Deslanoside

This classification denotes a glycoside and cardiotonic agent with the molecular formula C47H74O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YGY317RK75, chemically known as 3beta-(o-beta-d-glucopyranosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-beta-d-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid but generally known as deslanoside, which bears US NIH Compound Identifier 28620. European Medicines Agency schedules Deslanoside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06997MIG. The term DESLANOSIDE is an International Non-Proprietary Name. World Health Organization schedules deslanoside in its Anatomical Therapeutic Chemical (ATC) Classification. DESLANOSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule deslanoside under HS 29389010 and SITC 54161. As of Q4 2014, DESLANOSIDE remains the US FDA Preferred Term for this commodity. Deslanoside bears US NLM identifiers UMLS ID C0011689 and NCI Concept Code C65368. SMILES: OC12C3C(C4(C(CC3)CC(OC3OC(C(OC5OC(C(OC6OC(C(OC7OC(C(O)C(O)C7O)CO)C(O)C6)C)C(O)C5)C)C(O)C3)C)CC4)C)CC(O)C1(C(CC2)C1=CC(=O)OC1)C.